Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV119 in Chinese Healthy Adult Subjects and Patients With Schizophrenia
NCT06504290Phase 1Recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VV119 in schizophrenia (4 arms), sponsored by Vigonvita Life Sciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2024; status: recruiting.
02
Drugs
VV119
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06504290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504290.